
Harrow Health Inc (HROW) - Financial and Strategic SWOT Analysis Review
Description
Harrow Health Inc (HROW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Harrow Health Inc (Harrow Health) formerly known as Imprimis Pharmaceuticals Inc, owns a portfolio of healthcare businesses which also includes ImprimisRx, the ophthalmology pharmaceutical compounding business in the US and holds large equity positions in Eton Pharmaceuticals, Melt Pharmaceuticals and Surface Pharmaceuticals. The company is focused on developing innovative medications to serve ophthalmology industry in the marketplace. The company through its subsidiaries develops injectable Dropless Therapy formulations and topical LessDrops formulations. MAY-44 for treating dyspareunia and MAY-88 for treating interstitial cystitis and among others. Harrow Health is headquartered in Nashville, Tennessee, the US.
Harrow Health Inc Key Recent Developments
May 11,2023: Harrow Announces First Quarter 2023 Financial Results
May 02,2023: Harrow launches ILEVRO, NEVANAC, and MAXIDEX in the U.S.
Mar 23,2023: Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
Feb 15,2023: Harrow launches next-generation compounded atropine formulations
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
52 Pages
- Section 1 - About the Company
- Harrow Health Inc - Key Facts
- Harrow Health Inc - Key Employees
- Harrow Health Inc - Key Employee Biographies
- Harrow Health Inc - Major Products and Services
- Harrow Health Inc - History
- Harrow Health Inc - Company Statement
- Harrow Health Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Harrow Health Inc - Business Description
- R&D Overview
- Harrow Health Inc - Corporate Strategy
- Harrow Health Inc - SWOT Analysis
- SWOT Analysis - Overview
- Harrow Health Inc - Strengths
- Harrow Health Inc - Weaknesses
- Harrow Health Inc - Opportunities
- Harrow Health Inc - Threats
- Harrow Health Inc - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Harrow Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Harrow Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Harrow Health Inc, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- May 11, 2023: Harrow Announces First Quarter 2023 Financial Results
- May 02, 2023: Harrow launches ILEVRO, NEVANAC, and MAXIDEX in the U.S.
- Mar 23, 2023: Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
- Feb 15, 2023: Harrow launches next-generation compounded atropine formulations
- Dec 15, 2022: Harrow to acquire US rights to Novartis’ ophthalmic products
- Nov 30, 2022: Harrow and iOR Partners Expand National Product Supply Agreement
- Nov 14, 2022: Harrow Announces Third Quarter 2022 Financial Results
- Nov 10, 2022: Harrow Launches Atropine.com
- Aug 11, 2022: Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
- Aug 09, 2022: Harrow Health Announces Second Quarter 2022 Financial Results
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Harrow Health Inc, Key Facts
- Harrow Health Inc, Key Employees
- Harrow Health Inc, Key Employee Biographies
- Harrow Health Inc, Major Products and Services
- Harrow Health Inc, History
- Harrow Health Inc, Subsidiaries
- Harrow Health Inc, Key Competitors
- Harrow Health Inc, Ratios based on current share price
- Harrow Health Inc, Annual Ratios
- Harrow Health Inc, Annual Ratios (Cont...1)
- Harrow Health Inc, Annual Ratios (Cont...2)
- Harrow Health Inc, Interim Ratios
- Harrow Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Harrow Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Harrow Health Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Harrow Health Inc, Performance Chart (2018 - 2022)
- Harrow Health Inc, Ratio Charts
- Harrow Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Harrow Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.